160 related articles for article (PubMed ID: 30088238)
1. Silencing VEGF-B Diminishes the Neuroprotective Effect of Candesartan Treatment After Experimental Focal Cerebral Ischemia.
Ishrat T; Soliman S; Eldahshan W; Pillai B; Ergul A; Fagan SC
Neurochem Res; 2018 Oct; 43(10):1869-1878. PubMed ID: 30088238
[TBL] [Abstract][Full Text] [Related]
2. Sequential Therapy with Minocycline and Candesartan Improves Long-Term Recovery After Experimental Stroke.
Soliman S; Ishrat T; Fouda AY; Patel A; Pillai B; Fagan SC
Transl Stroke Res; 2015 Aug; 6(4):309-22. PubMed ID: 26004281
[TBL] [Abstract][Full Text] [Related]
3. Protective mechanisms of the angiotensin II type 1 receptor blocker candesartan against cerebral ischemia: in-vivo and in-vitro studies.
Liu H; Kitazato KT; Uno M; Yagi K; Kanematsu Y; Tamura T; Tada Y; Kinouchi T; Nagahiro S
J Hypertens; 2008 Jul; 26(7):1435-45. PubMed ID: 18551021
[TBL] [Abstract][Full Text] [Related]
4. Low-dose candesartan enhances molecular mediators of neuroplasticity and subsequent functional recovery after ischemic stroke in rats.
Ishrat T; Pillai B; Soliman S; Fouda AY; Kozak A; Johnson MH; Ergul A; Fagan SC
Mol Neurobiol; 2015; 51(3):1542-53. PubMed ID: 25084762
[TBL] [Abstract][Full Text] [Related]
5. Candesartan induces a prolonged proangiogenic effect and augments endothelium-mediated neuroprotection after oxygen and glucose deprivation: role of vascular endothelial growth factors A and B.
Soliman S; Ishrat T; Pillai A; Somanath PR; Ergul A; El-Remessy AB; Fagan SC
J Pharmacol Exp Ther; 2014 Jun; 349(3):444-57. PubMed ID: 24681872
[TBL] [Abstract][Full Text] [Related]
6. Comparison between early and delayed systemic treatment with candesartan of rats after ischaemic stroke.
Brdon J; Kaiser S; Hagemann F; Zhao Y; Culman J; Gohlke P
J Hypertens; 2007 Jan; 25(1):187-96. PubMed ID: 17143191
[TBL] [Abstract][Full Text] [Related]
7. Brain-Derived Neurotrophic Factor Knockdown Blocks the Angiogenic and Protective Effects of Angiotensin Modulation After Experimental Stroke.
Fouda AY; Alhusban A; Ishrat T; Pillai B; Eldahshan W; Waller JL; Ergul A; Fagan SC
Mol Neurobiol; 2017 Jan; 54(1):661-670. PubMed ID: 26758277
[TBL] [Abstract][Full Text] [Related]
8. Candesartan but not ramipril pretreatment improves outcome after stroke and stimulates neurotrophin BNDF/TrkB system in rats.
Krikov M; Thone-Reineke C; Müller S; Villringer A; Unger T
J Hypertens; 2008 Mar; 26(3):544-52. PubMed ID: 18300867
[TBL] [Abstract][Full Text] [Related]
9. Neuroprotective effects of AT1 receptor antagonists after experimental ischemic stroke: what is important?
Culman J; Jacob T; Schuster SO; Brolund-Spaether K; Brolund L; Cascorbi I; Zhao Y; Gohlke P
Naunyn Schmiedebergs Arch Pharmacol; 2017 Sep; 390(9):949-959. PubMed ID: 28669009
[TBL] [Abstract][Full Text] [Related]
10. Effect of angiotensin II type 1 receptor blocker, candesartan, and beta 1 adrenoceptor blocker, atenolol, on brain damage in ischemic stroke.
Saad MA; Abbas AM; Boshra V; Elkhateeb M; El Aal IA
Acta Physiol Hung; 2010 Jun; 97(2):159-71. PubMed ID: 20511125
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of acute neurovascular protection with AT1 blockade after stroke: Effect of prestroke hypertension.
Alhusban A; Kozak A; Pillai B; Ahmed H; Sayed MA; Johnson MH; Ishrat T; Ergul A; Fagan SC
PLoS One; 2017; 12(6):e0178867. PubMed ID: 28640888
[TBL] [Abstract][Full Text] [Related]
12. Candesartan augments ischemia-induced proangiogenic state and results in sustained improvement after stroke.
Kozak A; Ergul A; El-Remessy AB; Johnson MH; Machado LS; Elewa HF; Abdelsaid M; Wiley DC; Fagan SC
Stroke; 2009 May; 40(5):1870-6. PubMed ID: 19265050
[TBL] [Abstract][Full Text] [Related]
13. Study of Neuroprotection by a Combination of the Biological Antioxidant (
Trabolsi C; Takash Chamoun W; Hijazi A; Nicoletti C; Maresca M; Nasser M
Molecules; 2021 Feb; 26(4):. PubMed ID: 33562701
[TBL] [Abstract][Full Text] [Related]
14. The angiotensin II type 1-receptor blocker candesartan increases cerebral blood flow, reduces infarct size, and improves neurologic outcome after transient cerebral ischemia in rats.
Engelhorn T; Goerike S; Doerfler A; Okorn C; Forsting M; Heusch G; Schulz R
J Cereb Blood Flow Metab; 2004 Apr; 24(4):467-74. PubMed ID: 15087716
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic effects of postischemic treatment with hypotensive doses of an angiotensin II receptor blocker on transient focal cerebral ischemia.
Fu H; Hosomi N; Pelisch N; Nakano D; Liu G; Ueno M; Miki T; Masugata H; Sueda Y; Itano T; Matsumoto M; Nishiyama A; Kohno M
J Hypertens; 2011 Nov; 29(11):2210-9. PubMed ID: 21934531
[TBL] [Abstract][Full Text] [Related]
16. Postischemic administration of angiotensin II type 1 receptor blocker reduces cerebral infarction size in hypertensive rats.
Omura-Matsuoka E; Yagita Y; Sasaki T; Terasaki Y; Oyama N; Sugiyama Y; Okazaki S; Sakoda S; Kitagawa K
Hypertens Res; 2009 Jul; 32(7):548-53. PubMed ID: 19424281
[TBL] [Abstract][Full Text] [Related]
17. Hypertension after experimental cerebral ischemia: candesartan provides neurovascular protection.
Fagan SC; Kozak A; Hill WD; Pollock DM; Xu L; Johnson MH; Ergul A; Hess DC
J Hypertens; 2006 Mar; 24(3):535-9. PubMed ID: 16467657
[TBL] [Abstract][Full Text] [Related]
18. Reduction of cerebral infarct size by the AT1-receptor blocker candesartan, the HMG-CoA reductase inhibitor rosuvastatin and their combination. An experimental study in rats.
Engelhorn T; Doerfler A; Heusch G; Schulz R
Neurosci Lett; 2006 Oct; 406(1-2):92-6. PubMed ID: 16901636
[TBL] [Abstract][Full Text] [Related]
19. A comparative study of neuroprotective effect of single and combined blockade of AT1 receptor and PARP-1 in focal cerebral ischaemia in rat.
Singh N; Sharma G; Singh N; Hanif K
Int J Stroke; 2014 Jul; 9(5):560-8. PubMed ID: 23013350
[TBL] [Abstract][Full Text] [Related]
20. Neuroprotective effects of candesartan against cerebral ischemia in spontaneously hypertensive rats.
Lu Q; Zhu YZ; Wong PT
Neuroreport; 2005 Nov; 16(17):1963-7. PubMed ID: 16272888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
